StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 
 
 
Vertex Pharma
430.11
+0.78%
 

VRTX

 

Vertex Pharma

$ 430.11

 
+$3.33 | +0.78%
 
 
Open
$ 430
 
 
MKT CAP
$ 111.10B
 
High
$ 434.50
 
 
VOL
$ 745.76K
 
Low
$ 429.07
 
 
AVG VOL
$ 1.61M
 
 
 

VRTX Stock Analysis

  Login to display Vertex Pharma (VRTX) recommendation from the last 90 days from financial news and social media.
 
 

VRTX Total Score

 

Chart

 
 

430.08

353.04

368

291.23

 
 
1month
3month
6month
1year
 
Total Return
VRTX
vs.
S&P500
 

 
1-week Return
+0.90%
 
+1.17%
 
 
5-week Return
-0.66%
 
+6.44%
 
 
10-week Return
+20.72%
 
+10.09%
 
 
 
 

Strengths

VRTX Rewards

 Earnings are forecast to grow

VRTX Rewards

 Outperform the market

 

Risk Analysis

VRTX Risk Analysis

 Downgraded on weak valued

VRTX Risk Analysis

 Investors losing their confidence

 
 

VRTX Risk Level

This Indicator assigning risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
VRTX Risk Level
LOW
HIGH

Risk Volatility

 

VRTX has Low Risk Level

Click here to check what is your level of risk

 

VRTX Analysts Opinion

The company overall standing based on key factors, offering insights into analysts perspectives and market expectations. Hover over the category for more information

 
 

Earnings

×
 

Earnings

4.00
 

VRTX Earnings Sentiment

 Above analyst estimates

 
 

Rating

×
 

Rating

1.67
 

VRTX Rating Sentiment

 Downgraded on weak valued

 

Momentum

×
 

Momentum

3.13
 

VRTX Momentum Analysis

 Has been gaining momentum

 

Activity

×
 

Activity

3.94
 

VRTX Activity Sentiment

 Investors losing their confidence

 

Future

×
 

Future

3.23
 

VRTX Future Sentiment

 Earnings are forecast to grow

VRTX Future Sentiment

 Outperform the market

 
 

VRTX Analysts Opinion

VRTX Analysts opinion is negative and has getting worse from the past 3 months

 

VRTX Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
81%
Buy
Opinion
Trend
Score
Potential
Score
 
 
0%
50%
69%
 
On Track
On Track
On Track
 

VRTX Street Opinion 

VRTX Street view is extremely ish and have positive views on the near-term outlook

 

VRTX Performance Sentiment

Sentiments overview associated with the company events and the stock performance.
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
Contrasts the positive and negative sentiments surrounding the company performance.
 
81%
17%
Positive
Negative
51 out of 63
events present
11 out of 63
events present
 
 

VRTX Earnings

The Trailing Twelve Months (TTM) reflects 12-month period, providing rview of VRTX financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
9,654
8,931
7,574
+12.90%
 
 
Cost of Revenue
1,178
1,080
904
+14.15%
 
 
Gross Profit
8,477
7,850
6,670
+12.73%
 
 
Operating Expense
4,067
3,485
2,778
+21.00%
 
 
Operating Income
4,409
4,365
3,892
+6.43%
 
 
Net Interest Income
476
90
-57
-
 
 
Interest Expense
45
55
62
-14.81%
 
 
Interest Income
521
145
5
+920.78%
 
 
Other Income
-577
-223
-1,105
-
 
 
EPS
13.48
12.97
9.09
+21.78%
 
 
Next Earnings Date: Apr 29, 2024
 
Highlights
Last Modify
Price
% Change

 
New Product
This Week
420.64
-0.37%
 
Approvals
1 Week Ago
416.04
-0.59%
 
New Product
1 Week Ago
418.53
-1.04%
 
HR Activity
2 Weeks Ago
419.08
+0.71%
 
Strong Earnings
2 Weeks Ago
415.98
-3.01%
 
 

VRTX Latest News Feed
































 
 
 
joker
 
 
 
StocksRunner

Explore our VRTX Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our VRTX Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

VRTX Rewards

 Earnings are forecast to grow

VRTX Rewards

 Outperform the market

 

Risk Analysis

 

VRTX Risk Analysis

 Downgraded on weak valued

VRTX Risk Analysis

 Investors losing their confidence

 
 
 

VRTX Risk Level

 
 
 

The Indicator assigning risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
VRTX Risk Level
LOW
HIGH

Risk Volatility

 

VRTX has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

VRTX

 

Vertex Pharma

$ 430.11

 
+$3.33 | +0.78%
 
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 430
 
 
MKT CAP
$ 111.10B
 
High
$ 434.50
 
 
VOL
$ 745.76K
 
Low
$ 429.07
 
 
AVG VOL
$ 1.61M
 
 
 

VRTX Analysis

  Sign in to view Vertex Pharma (VRTX) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

430.08

353.04

368

291.23

 
 
1month
3month
6month
1year
 
Total Return
VRTX
vs.
S&P500
 

 
1-week Return
+0.90%
 
+1.17%
 
 
5-week Return
-0.66%
 
+6.44%
 
 
10-week Return
+20.72%
 
+10.09%
 
 
 

VRTX Analysts Opinion

Overall standing by considering key factors, reflecting analysts perspectives and market expectations. Hover over the category for more information

 
 

Earnings

×
 

Earnings

4.00
 

VRTX Earnings Sentiment

 Above analyst estimates

 
 

Rating

×
 

Rating

1.67
 

VRTX Rating Sentiment

 Downgraded on weak valued

 

Momentum

×
 

Momentum

3.13
 

VRTX Momentum Sentiment

 Has been gaining momentum

 

Activity

×
 

Activity

3.94
 

VRTX Activity Sentiment

 Investors losing their confidence

 

Future

×
 

Future

3.23
 

VRTX Future Sentiment

 Earnings are forecast to grow

VRTX Future Sentiment

 Outperform the market

 
 

VRTX Analysts Opinion

VRTX Analysts opinion is negative and has getting worse from the past 3 months

 

VRTX Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
81%
Buy
Opinion
Trend
Score
Potential
Score
 
 
0%
50%
69%
 
On Track
On Track
On Track
 

VRTX Street Opinion 

VRTX Street view is extremely ish and have positive views on the near-term outlook

 
VRTX Performance Sentiment
Sentiments overview associated with the company events and the stock performance.
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
Contrasts the positive and negative sentiments surrounding the company performance.
 
81%
17%
Positive
Negative
51 out of 63
events present
11 out of 63
events present
 

 

VRTX Earnings

The Trailing Twelve Months (TTM) data reflects the most recent 12-month period, providing overview of VRTX financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
9,654
8,931
7,574
+12.90%
 
 
Cost of Revenue
1,178
1,080
904
+14.15%
 
 
Gross Profit
8,477
7,850
6,670
+12.73%
 
 
Operating Expense
4,067
3,485
2,778
+21.00%
 
 
Operating Income
4,409
4,365
3,892
+6.43%
 
 
Net Interest Income
476
90
-57
-
 
 
Interest Expense
45
55
62
-14.81%
 
 
Interest Income
521
145
5
+920.78%
 
 
Other Income
-577
-223
-1,105
-
 
 
EPS
13.48
12.97
9.09
+21.78%
 
 
Next Earnings Date: Apr 29, 2024
 
Highlights
Last Modify
Price
% Change

 
New Product
This Week
420.64
-0.37%
 
Approvals
1 Week Ago
416.04
-0.59%
 
New Product
1 Week Ago
418.53
-1.04%
 
HR Activity
2 Weeks Ago
419.08
+0.71%
 
Strong Earnings
2 Weeks Ago
415.98
-3.01%
 
 
VRTX Latest News Feed

Vertex Pharmaceuticals (VRTX) Price Target Increased by 11.27% to 474.94. The average one-year price target for Vertex Pharmaceuticals (NasdaqGS:VRTX) has been revised to 474.94 / share. This is an increase of 11.27% from the

Sat Feb 24, 2024

Potential

Vertex gets EU backing for label expansion of Kalydeco in cystic fibrosis.

Fri Feb 23, 2024

Activity

What Analysts Are Saying About Vertex Pharmaceuticals Stock. During the last three months 20 analysts shared their evaluations of Vertex Pharmaceuticals (NASDAQ:) revealing diverse outlooks from ish to bearish. The following table provides a quick overvi

Tue Feb 20, 2024

Potential

Vertex Pharmaceuticals Is About to Extend Its Leadership in This Billion-Dollar Market. Vertex Pharmaceuticals (NASDAQ: VRTX) has wowed investors in recent times as its expanded beyond its specialty area of cystic fibrosis (CF) treatment. The co

Tue Feb 20, 2024

Activity

Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Heres Why Thats a Smart Move.. Hot off the approval of its gene therapy for a pair of rare hereditary blood disorders Vertex Pharmaceuticals (NASDAQ: VRTX) will soon have

Sat Feb 17, 2024

Activity

Vertex (VRTX) CRSPs Casgevy Gets EU Nod for Two Blood Disorders. Vertex Pharmaceuticals VRTX and partner CRISPR Therapeutics CRSP announced that the European Commission has granted conditional

Wed Feb 14, 2024

Activity

Vertex : EU Okays Casgevy For Sickle Cell Disease & Transfusion-Dependent Beta Thalassemia Treatment. (RTTNews) - The European Commission has granted conditional marketing authorization to Casgevy a CRISPR/Cas9 gene-edited therapy. Casgevy is ap

Tue Feb 13, 2024

Activity

Vertex CRISPR gene therapy approved in EU for sickle cell disease beta-thalassemia.

Tue Feb 13, 2024

Activity

Vertex Global Survey Reveals the Regions Championing and Struggling with Indirect Tax Compliance With the United States Taking the Lead. LONDON Feb. 12 2024 (GLOBE NEWSWIRE) -- According to research conducted by Vertex Inc. VERX (".Vertex". or the &

Mon Feb 12, 2024

Activity

cervomed announces appointment of industry leader joshua boger ph.d. as chair of the board. dr. boger is the founder and retired ceo and board chair of vertex pharmaceuticals

Wed Feb 7, 2024

Activity
Potential

vertexs next-generation cystic fibrosis program shows efficacy with reduced burden provides growth opportunity: goldman sachs. monday) released results from its once-daily vanzacaftor/tezacaftor/deutivacaftor (vanza triple) program for cystic fibrosis (cf

Tue Feb 6, 2024

Activity
Potential

vertex stock downgraded amid valuation high and pain franchise headwinds.

Tue Feb 6, 2024

Potential
Rating

vertexs (vrtx) q4 earnings and sales surpass estimates. vertex pharmaceuticals incorporated vrtx reported fourth-quarter 2023 adjusted earnings per share of $4.20 which beat the zacks consensus

Tue Feb 6, 2024

Earnings

vertex pharmaceuticals has a $10 billion opportunity on the table. heres how you can invest. vertex pharmaceuticals (nasdaq: vrtx) has a knack for finding profitable niches and it looks like its on track to do so again in the field of pain relie

Tue Feb 6, 2024

Potential

vertex pharmaceuticals triple combo treatment for lung disorder meets primary goal in adult and pediatric patients. vertex pharmaceuticals incorporated vrtx released results from its once-daily vanzacaftor/tezacaftor/deutivacaftor (vanza triple) program f

Tue Feb 6, 2024

Activity

vertex pharmaceuticals (vrtx) q4 earnings and revenues top estimates. vertex pharmaceuticals (vrtx) came out with quarterly earnings of $4.20 per share beating the zacks consensus estimate of $

Mon Feb 5, 2024

Earnings

vertex to seek fda ema approval for cf therapy by mid-2024.

Mon Feb 5, 2024

Activity

vertex pharmaceuticals inc. q4 profit increases beats estimates. (rttnews) - vertex pharmaceuticals inc. (vrtx) reported a profit for its fourth quarter that increased from the same period last year and beat the street estimates.

Mon Feb 5, 2024

Earnings

vertexs next-gen cystic fibrosis drug scores big. shares rise on quarterly beat.

Mon Feb 5, 2024

Earnings
Momentum

vertex pharmaceuticals non-gaap eps of $4.20 beats by $0.11 revenue of $2.52b beats by $10m.

Mon Feb 5, 2024

Earnings

vertexs (vrtx) non-opioid pain drug meets primary goal. vertex pharmaceuticals vrtx announced positive results from three late-stage studies on its investigational orally-administered non-opioi

Wed Jan 31, 2024

Activity

vertex pharma downgraded at baird on modest efficacy in pain med.

Wed Jan 31, 2024

Activity
Rating

why vertex pharmaceuticals stock topped the market today. good news from the lab sparked a mini-rally in vertex pharmaceuticals (nasdaq: vrtx) stock on tuesday. the biotechs shares closed the trading session more than 2% higher in price which wa

Wed Jan 31, 2024

Potential

vertexs pain drug succeeds in late-stage studies marking major breakthrough in search for new non-opioid medicines. an ex­per­i­men­tal non-opi­oid drug low­ered pain lev­els in a se­ries of piv­otal stud­ies ac­cord­ing to the drugs de­vel­op­er ver­tex

Tue Jan 30, 2024

Activity

vertex non-opioid pain drug meets main goal in late-stage trials. vertex pharmaceuticals said on tuesday its experimental drug for treating post-surgical pain succeeded in a pair of late-stage trials a major milestone in the companys decades-lon

Tue Jan 30, 2024

Activity

vertex stock rises as non-opioid pain drug shows positive results in pivotal trials.

Tue Jan 30, 2024

Activity
Momentum

vertex unveils strong data on opioid alternative.

Tue Jan 30, 2024

Activity

vertex pharmaceuticals (vrtx) laps the stock market: heres why. in the latest market close vertex pharmaceuticals (vrtx) reached $435.82 with a 1.31% movement compared to the previous day. this

Mon Jan 29, 2024

Momentum
Momentum

vertex energy plunges to two-and-a-half-year low as fitch cuts default rating.

Wed Jan 24, 2024

Momentum

canaccord cuts vertex to sell cites recent price run-up.

Wed Jan 24, 2024

Rating

 
 
 
 
 

Score Tracker

 
 
 
Based on 63 events in the last 90 days from financial news and social media. Last updated Feb 23, 2024 13:28 Wall St. time
 
 

VRTX Total Score

 
 
 
 
 
 
 
StocksRunner

Discover VRTX Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of VRTX. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our VRTX Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

VRTX Stock trends

VRTX Stock performance

VRTX Stock analysis

VRTX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker